Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherNon-Current ReceivablesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)
Ratios

ImmunityBio (IBRX) Long-Term Debt Issuances (2020 - 2024)

Historic Long-Term Debt Issuances for ImmunityBio (IBRX) over the last 5 years, with Q2 2024 value amounting to $97.0 million.

  • ImmunityBio's Long-Term Debt Issuances rose 22481.07% to $97.0 million in Q2 2024 from the same period last year, while for Sep 2025 it was $97.0 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $97.0 million for FY2024, which is 6252.18% down from last year.
  • Latest data reveals that ImmunityBio reported Long-Term Debt Issuances of $97.0 million as of Q2 2024, which was up 22481.07% from $199.0 million recorded in Q3 2023.
  • Over the past 5 years, ImmunityBio's Long-Term Debt Issuances peaked at $298.5 million during Q4 2021, and registered a low of $29.8 million during Q1 2023.
  • In the last 5 years, ImmunityBio's Long-Term Debt Issuances had a median value of $63.7 million in 2020 and averaged $103.6 million.
  • Per our database at Business Quant, ImmunityBio's Long-Term Debt Issuances plummeted by 8333.33% in 2022 and then surged by 22481.07% in 2024.
  • ImmunityBio's Long-Term Debt Issuances (Quarter) stood at $63.7 million in 2020, then soared by 368.6% to $298.5 million in 2021, then plummeted by 83.33% to $49.8 million in 2022, then soared by 300.0% to $199.0 million in 2023, then tumbled by 51.28% to $97.0 million in 2024.
  • Its Long-Term Debt Issuances was $97.0 million in Q2 2024, compared to $199.0 million in Q3 2023 and $29.8 million in Q2 2023.